Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Chief Development Officer | January 31, 2024 | February 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZEVRA THERAPEUTICS, INC.
Report date January 31, 2024 · Filed February 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 77,000 |
Reported balance
After 2024-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-31 · Grant · Acquired 77,000 · Balance 77,000 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU"). F2: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU").
F2: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2024 Filed Feb 3, 2024 01:14 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 77,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003028 · rdgdoc.xml · derivative · entry 1 Mickle Christal M M · CIK 0001638366 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU"). F2 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 02:52 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001437749-23-000917 · rdgdoc.xml · derivative · entry 1 Mickle Christal M M · CIK 0001638366 · Chief Product Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-01-08 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 6, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 20:34 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,000 | $4.10 | $8,199.00 |
DisclosureSEC source: 0001437749-17-005236 · rdgdoc.xml · nonDerivative · entry 1 Mickle Christal M M · CIK 0001638366 · VP, Operations & Product Dvlp. · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Mickle Investments LLC Disclosed balance after: 9,050 F1 · ownership.direct: The Reporting Person and her spouse are the managing members of Mickle Investments LLC. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:56 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001437749-17-001387 · rdgdoc.xml · derivative · entry 2 Mickle Christal M M · CIK 0001638366 · VP, Operations & Product Dvlp. · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-01-26 F2 · derivative.exercise_date: Grant to the Reporting Person's spouse of a stock option under the Plan. 25% of the shares will vest on January 27, 2018 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person's spouse is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:56 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001437749-17-001387 · rdgdoc.xml · derivative · entry 1 Mickle Christal M M · CIK 0001638366 · VP, Operations & Product Dvlp. · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 27, 2018 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| January 27, 2017 Filed Mar 24, 2017 20:34 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 71,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-005236 · rdgdoc.xml · nonDerivative · entry 5 Mickle Christal M M · CIK 0001638366 · VP, Operations & Product Dvlp. · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Travis C Mickle & Christal M.M. Mickle TRS UA 4-30-09 Mickle Family Trust, co-trustee with spouse Disclosed balance after: 159,550 Read SEC document |
| January 27, 2017 Filed Mar 24, 2017 20:34 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 144,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-005236 · rdgdoc.xml · nonDerivative · entry 4 Mickle Christal M M · CIK 0001638366 · VP, Operations & Product Dvlp. · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Travis C Mickle & Christal M.M. Mickle TRS UA 4-30-09 TCM Family Trust, co-trustee with spouse Disclosed balance after: 85,907 Read SEC document |
| January 27, 2017 Filed Mar 24, 2017 20:34 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 71,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-005236 · rdgdoc.xml · nonDerivative · entry 3 Mickle Christal M M · CIK 0001638366 · VP, Operations & Product Dvlp. · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,597,343 Read SEC document |
| January 27, 2017 Filed Mar 24, 2017 20:34 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GiftCommon Stock | 144,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-005236 · rdgdoc.xml · nonDerivative · entry 2 Mickle Christal M M · CIK 0001638366 · VP, Operations & Product Dvlp. · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,526,081 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.